text
"['\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2023년 03월 31일\n)\n(단위 : 백만원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nHPI, INC..\n비상장\n2007.09.14\n해외임상시험\n187\n200,200\n100.0\n75\n-\n-\n-\n200,200\n100.0\n75\n923\n547\nImmunoMet Therapeutics, Inc\n비상장\n2015.08.24\n투자\n2,173\n1,285,412\n15.95\n15,541\n-\n-\n-\n1,285,412\n15.95\n15,541\n5,026\n-498\nImmunovant, Inc.\n상장\n2019.01.11\n투자\n5,609\n939,395\n0.81\n21,131\n-\n-\n-2,134\n939,395\n0.81\n18,997\n672\n-200\nNurron Pharmaceuticals INC\n비상장\n2021.07.19\n투자\n571\n58,343\n2.37\n571\n-\n-\n-\n58,343\n2.37\n571\n1,709\n-600\nAlloplex Biotherapeutics, inc.\n비상장\n2023.01.27\n투자\n827\n-\n-\n577\n9,793\n250\n-\n9,793\n0.27\n827\n4,539\n-6,361\n합 계\n2,483,350\n-\n37,895\n9,793\n250\n-2,134\n2,493,143\n-\n36,011\n12,869\n-7,112\n']"
